| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
| Targets |
Boc-NH-PEG12-NH2 does not possess a specific pharmacological target of its own. Its function is chemical rather than biological—the Boc-protected amine and free primary amine provide reactive handles for bioconjugation. The compound's role in PROTAC synthesis is structural: it serves as a linker that connects an E3 ubiquitin ligase ligand to a target protein ligand. The PEG12 spacer provides optimal length (approximately 5-6 nm in extended conformation) and flexibility for ternary complex formation in PROTACs. The Boc group allows for selective deprotection and subsequent conjugation to carboxylate-containing ligands via amide bond formation, while the free amine can be directly conjugated to carboxylate-containing ligands. The compound itself does not interact with any enzyme, receptor, or signaling pathway.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
The in vitro activity of Boc-NH-PEG12-NH2 is evaluated primarily through its chemical reactivity rather than biological activity. The Boc-protected amine's deprotection efficiency is assessed by treating the compound with acid (e.g., TFA) and monitoring the appearance of the free amine by HPLC, LC-MS, or ninhydrin assay. The free primary amine's reactivity is evaluated by conjugation to carboxylate-containing model compounds (e.g., via EDC/NHS coupling), with reaction progress monitored by analytical techniques. In the context of PROTAC synthesis, Boc-NH-PEG12-NH2 serves as a linker component, and its contribution to the final PROTAC's ability to induce target protein degradation is assessed in cell-based degradation assays. The long PEG12 spacer provides excellent aqueous solubility, which is critical for maintaining the solubility of hydrophobic PROTAC molecules. |
| ln Vivo |
As a non-therapeutic linker, Boc-NH-PEG12-NH2 does not exhibit intrinsic in vivo activity. Its applications in vivo are realized through the conjugates prepared using this reagent. The compound's PEG12 spacer provides excellent hydrophilicity that can improve the solubility, reduce aggregation, and extend circulation half-life of the resulting conjugates. In drug delivery applications, Boc-NH-PEG12-NH2 can be used to PEGylate therapeutic proteins, peptides, or nanoparticles for improved pharmacokinetic properties. The Boc-protected amine allows for selective deprotection and subsequent conjugation to targeting ligands or therapeutic payloads, while the free amine provides an immediate conjugation site. The compound's heterobifunctional design enables the preparation of defined conjugates with two different functional groups.
|
| Enzyme Assay |
Characterization of Boc-NH-PEG12-NH2 involves standard analytical techniques for PEG-based compounds. Purity is typically assessed by HPLC, with the compound available at high purity. Nuclear magnetic resonance (NMR) spectroscopy (¹H and ¹³C) confirms the chemical structure and the presence of the Boc group, while mass spectrometry (MS) provides accurate molecular weight confirmation. The Boc group can be detected by characteristic NMR signals (tert-butyl protons at ~1.4 ppm), and its removal can be monitored by the disappearance of these signals upon acid treatment. The PEG12 spacer can be confirmed by the characteristic NMR signals of ethylene oxide units. The compound's molecular weight is 688.84 and its molecular formula is C31H64N2O14. The compound should be stored at -20°C to maintain stability.
|
| Cell Assay |
Cell-based studies involving Boc-NH-PEG12-NH2 are typically conducted in the context of PROTAC research. The compound is used as a linker in the synthesis of bifunctional degraders. The resulting PROTACs are evaluated in cell lines for target protein degradation efficacy via Western blot, typically at concentrations ranging from nanomolar to micromolar. The long PEG12 spacer provides excellent aqueous solubility, which is important for maintaining the solubility of the PROTAC in cell culture media. The Boc-protected amine can be deprotected to a free amine for conjugation to fluorescent dyes or affinity tags for mechanistic studies of cellular uptake and intracellular distribution. Cellular uptake of PROTACs incorporating this linker can be assessed by fluorescence microscopy or flow cytometry.
|
| Animal Protocol |
In vivo applications of Boc-NH-PEG12-NH2 are realized through the conjugates prepared using this reagent. The compound's long PEG12 spacer provides excellent hydrophilicity that can reduce non-specific protein binding and improve the pharmacokinetic profile of the conjugate. In drug delivery applications, Boc-NH-PEG12-NH2 can be used to PEGylate therapeutic proteins or nanoparticles for extended circulation half-life. The Boc-protected amine allows for selective deprotection and subsequent conjugation to targeting ligands for active targeting applications, while the free amine provides an immediate conjugation site. In PROTAC research, the complete PROTAC molecules incorporating this linker are evaluated in mouse xenograft models for antitumor efficacy, pharmacokinetics, and pharmacodynamics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Boc-NH-PEG12-NH2 itself are not typically characterized, as the compound is a research reagent rather than a drug candidate. In the context of PEGylated conjugates, the long PEG12 spacer contributes to the overall hydrophilicity and solubility, which can significantly reduce clearance and extend circulation half-life. The compound's molecular weight of 688.84 is substantial for a PEG linker. Storage recommendations include -20°C for long-term storage, with the compound stable as a powder for up to 3 years. The compound is stable for shipping at ambient temperature for short periods. Solubility is expected to be excellent in aqueous buffers and organic solvents due to the hydrophilic PEG12 spacer. The Boc group provides stability during storage and handling.
|
| Toxicity/Toxicokinetics |
As a research chemical, Boc-NH-PEG12-NH2 is not intended for human or veterinary use, and comprehensive toxicological data are not extensively reported in the available literature. Standard laboratory safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety glasses) and proper ventilation. PEG-based compounds are generally considered to have low intrinsic toxicity due to their biocompatibility and lack of specific biological activity. The compound is not classified as hazardous under normal handling conditions. It should be stored under recommended conditions to maintain stability and prevent degradation.
|
| References | |
| Additional Infomation |
Boc-NH-PEG12-NH2 is a heterobifunctional PEG linker featuring a Boc-protected amine and a free primary amine separated by a long PEG12 spacer. It is classified as a PEG-based PROTAC linker and is used in the synthesis of targeted protein degraders. The compound is widely applied in drug delivery, nanomedicine, and bioconjugation research. It is not approved for clinical use and has no marketed drug products. Synonyms include tert-butyl (38-amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxaoctatriacontyl)carbamate. The compound is available from multiple chemical suppliers.
|
| Molecular Formula |
C31H64N2O14
|
|---|---|
| Molecular Weight |
688.844871520996
|
| Exact Mass |
688.435
|
| CAS # |
1642551-09-4
|
| PubChem CID |
137346699
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
47
|
| Complexity |
632
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN
|
| InChi Key |
USZAQHILQQTIAZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H64N2O14/c1-31(2,3)47-30(34)33-5-7-36-9-11-38-13-15-40-17-19-42-21-23-44-25-27-46-29-28-45-26-24-43-22-20-41-18-16-39-14-12-37-10-8-35-6-4-32/h4-29,32H2,1-3H3,(H,33,34)
|
| Chemical Name |
tert-butyl N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate
|
| Synonyms |
BocNHPEG12NH2; Boc NH PEG12 NH2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~145.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4517 mL | 7.2586 mL | 14.5172 mL | |
| 5 mM | 0.2903 mL | 1.4517 mL | 2.9034 mL | |
| 10 mM | 0.1452 mL | 0.7259 mL | 1.4517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
